Sunday, December 29, 2024

Plasma miRNAs Correlate with Structural Brain and Cardiac Damage in Friedreich’s Ataxia

›
Peluzzo, T.M., Vieira, A.S., Matos, A.H.B. et al. Plasma miRNAs Correlate with Structural Brain and Cardiac Damage in Friedreich’s Ataxia. C...

Management of Friedreich Ataxia–Associated Cardiomyopathy in Pregnancy: A Review of the Literature

›
Management of Friedreich Ataxia–Associated Cardiomyopathy in Pregnancy: A Review of the Literature, Peterson, Ashleigh N. et al., American J...

Low expression of Frataxin might contribute to diabetic peripheral neuropathy in a mouse model

›
Siyu Xia, Lin Wu, Jing Chen, Kuanyu Li, Dezhi Bian, Low expression of Frataxin might contribute to diabetic peripheral neuropathy in a mouse...

Characterization of Arabidopsis thaliana FRATAXIN HOMOLOG in heme catabolism

›
Jing Zhang, Yingying Zhou, Qianyi Duan, Xinhe Xu, Xiao Wang, Jia Wang, Lin Liu, Characterization of Arabidopsis thaliana FRATAXIN HOMOLOG in...

Tachycardiomyopathy Treated With Ablation by Using 3D Mapping System in a Patient With Friedreich Ataxia

›
Hayıroğlu Mİ, Kalenderoğlu K, Gürkan K. Tachycardiomyopathy Treated With Ablation by Using 3D Mapping System in a Patient With Friedreich At...

Frataxin deficiency in the astrocytes drives neurocognitive impairment in sickle cell disease mice

›
Frataxin deficiency in the astrocytes drives neurocognitive impairment in sickle cell disease mice Enrico M Novelli, Shane Lenhart, Lesley M...
Friday, December 20, 2024

PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia

›
WARREN, N.J., Dec. 19, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the vatiquinone New Drug...
Monday, December 16, 2024

Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich’s Ataxia

›
December 16, 2024. Source: Larimar Therapeutics BALA CYNWYD, Pa., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (N...

Larimar Therapeutics Reports Positive Initial Data from Nomlabofusp OLE Study for Friedreich’s Ataxia

›
Dec. 16, 2024. Larimar Therapeutics announced positive results from its ongoing open label extension study evaluating the daily subcutaneous...
Saturday, December 14, 2024

Gradient of microstructural damage along the dentato- thalamo-cortical tract in Friedreich ataxia

›
Sirio Cocozza, Sara Bosticardo, Matteo Battocchio, Louise Corben, Martin Delatycki, Gary Egan, Nellie Georgiou-Karistianis, Serena Monti, Gi...